Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients

• Autor(a) principal: Pereira,Renata Freire Alves
• Data de Publicação: 2014
• Outros Autores: Garcia,Rita de Cássia Nasser Cubel, Azevedo,Kátia Martins Lopes de, Setúbal,Sérgio, Siqueira,Marilda Agudo Mendonça Teixeira de, Oliveira,Solange Artimos de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Memórias do Instituto Oswaldo Cruz
• Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014000200168
• topic: HIV; human parvovirus B19; seroconversion

Immunocompromised patients may develop severe chronic anaemia when infected by human parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus (HIV)-infected patients with good adherence to highly active antiretroviral treatment (HAART). In this study, we investigated the clinical evolution of five HIV-infected patients receiving HAART who had B19V infections confirmed by serum polymerase chain reaction. Four of the patients were infected with genotype 1a strains and the remaining patient was infected with a genotype 3b strain. Anaemia was detected in three of the patients, but all patients recovered without requiring immunoglobulin and/or blood transfusions. In all cases, the attending physicians did not suspect the B19V infections. There was no apparent relationship between the infecting genotype and the clinical course. In the HAART era, B19V infections in HIV-positive patients may be limited, subtle or unapparent.